- Report
- October 2025
- 160 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- October 2025
- 160 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- August 2025
- 150 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- January 2026
- 100 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- January 2026
- 127 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- June 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 480 Pages
Global
From €3153EUR$3,600USD£2,737GBP
- Report
- February 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- August 2025
- 130 Pages
Africa, Middle East
From €3503EUR$4,000USD£3,041GBP
- Report
- November 2025
- 160 Pages
Europe
From €3459EUR$3,950USD£3,003GBP
- Report
- October 2025
- 97 Pages
Asia Pacific
From €4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 99 Pages
United States
From €4248EUR$4,850USD£3,687GBP
- Report
- May 2024
- 224 Pages
Global
From €4203EUR$4,799USD£3,648GBP
- Report
- August 2024
- 443 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- November 2023
- 263 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- May 2023
- 251 Pages
Global
From €3832EUR$4,375USD£3,326GBP
- Report
- August 2023
- 395 Pages
Global
From €3678EUR$4,200USD£3,193GBP
- Report
- June 2022
- 327 Pages
Global
From €3065EUR$3,500USD£2,661GBP
- Report
- December 2024
- 180 Pages
Global
From €4073EUR$4,650USD£3,535GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more